Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Fasiglifam on Glycemic Control in Type 2 Diabetes
2013-000886-35Phase 2Terminated
- Sponsor
- Takeda
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in HbA1c at Week 12. Started Dec 2013; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-000886-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000886-35.